⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Triomed AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Triomed AB
↗Lund, Sweden
Triomed AB is a Swedish medical technology company based in Lund, dedicated to developing innovative therapeutic systems for peritoneal dialysis (PD). Their core focus is the 'Carry Life' platform, which utilizes a proprietary Steady Concentration Peritoneal Dialysis (SCPD) method to improve fluid and sodium removal while preserving membrane health for patients with end-stage renal disease (ESRD).
The company aims to overcome the limitations of conventional PD by providing portable, wearable dialysis solutions that allow patients to maintain their independence and preferred lifestyle. Triomed is currently in the clinical evaluation stage and has not yet received FDA clearance or CE marking for its flagship Carry Life UF system.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2005
Ownership:private
Status:operating
FUNDING
Stage:Later Stage VC
PIPELINE
Stage:Preclinical/Clinical
Lead Drug Stage:Pivotal clinical evaluation
Modalities:Medical Device
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:RegSmart Life Science AB (Regulatory support)
COMPETITION
Position:Emerging
Competitors:Baxter, Fresenius Medical Care
LEADERSHIP
Key Executives:
Marcello Grondelli - CEO
Hans Bengtsson - Development Lead of Active Devices
Katarina Holm - Finance and HR Manager
Scientific Founders:Lars Wramner, Anders Wallenås, Anders Helmner
Board Members:Patrick Greatrex, Anders Helmner, Anders Wallenås, Lars Wramner, Lars Persson
LINKS
Website:triomed.se
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Triomed AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.